- Home
- INSW vs SUPN Comparison
INSW vs SUPN Comparison
Compare INSW & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSW
- SUPN
- Stock Information
- Founded
- INSW 1999
- SUPN 2005
- Country
- INSW United States
- SUPN United States
- Employees
- INSW N/A
- SUPN N/A
- Industry
- INSW Semiconductors
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- INSW Technology
- SUPN Health Care
- Exchange
- INSW Nasdaq
- SUPN Nasdaq
- Market Cap
- INSW 1.7B
- SUPN 1.9B
- IPO Year
- INSW N/A
- SUPN 2012
- Fundamental
- Price
- INSW $39.94
- SUPN $32.44
- Analyst Decision
- INSW Buy
- SUPN Hold
- Analyst Count
- INSW 2
- SUPN 2
- Target Price
- INSW $52.00
- SUPN $36.00
- AVG Volume (30 Days)
- INSW 617.8K
- SUPN 531.0K
- Earning Date
- INSW 08-06-2025
- SUPN 08-05-2025
- Dividend Yield
- INSW 9.77%
- SUPN N/A
- EPS Growth
- INSW N/A
- SUPN N/A
- EPS
- INSW 6.47
- SUPN 1.11
- Revenue
- INSW $860,606,000.00
- SUPN $667,997,000.00
- Revenue This Year
- INSW N/A
- SUPN N/A
- Revenue Next Year
- INSW $2.05
- SUPN $12.02
- P/E Ratio
- INSW $6.33
- SUPN $29.78
- Revenue Growth
- INSW N/A
- SUPN 11.82
- 52 Week Low
- INSW $27.20
- SUPN $25.55
- 52 Week High
- INSW $60.99
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- INSW 66.28
- SUPN 51.84
- Support Level
- INSW $38.11
- SUPN $31.56
- Resistance Level
- INSW $41.17
- SUPN $33.15
- Average True Range (ATR)
- INSW 1.22
- SUPN 0.91
- MACD
- INSW 0.29
- SUPN -0.01
- Stochastic Oscillator
- INSW 95.06
- SUPN 56.30
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.